<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10065">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696423</url>
  </required_header>
  <id_info>
    <org_study_id>111535</org_study_id>
    <nct_id>NCT00696423</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children</brief_title>
  <official_title>Immunogenicity and Reactogenicity Study of GlaxoSmithKline Biologicals' Infanrix™/Hib Vaccine Administered as a Booster Dose to 18-24 Months Old Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol posting deals with objectives &amp; outcome measures of the booster phase. The
      objectives &amp; outcome measures of the primary phase are presented in a separate protocol
      posting (NCT number = NCT00412854). This Phase IIIB study will compare GSK Biologicals'
      DTPa/Hib vaccine to separately administered DTPa and Hib vaccines in Chinese children 18 to
      24 months of age, in terms of safety and immunogenicity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given in microgram per milliliter (μg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-diphtheria Toxoid Antibody Concentrations</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given in international Unit per milliliter (IU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-tetanus Toxoid Antibody Concentrations</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given in IU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</measure>
    <time_frame>One month after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP Antibody Concentrations</measure>
    <time_frame>Before booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given in μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-diphtheria Toxoid Antibody Concentrations</measure>
    <time_frame>Before booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given in IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tetanus Toxoid Antibody Concentrations</measure>
    <time_frame>Before booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given in IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</measure>
    <time_frame>Before booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean concentrations are given in EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</measure>
    <time_frame>Before booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms</measure>
    <time_frame>During the 4-day follow-up period after booster vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AE)</measure>
    <time_frame>During the 31-day follow-up period after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>During the 31-day follow-up period after booster vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in isability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">467</enrollment>
  <condition>Haemophilus Influenzae Type b Disease</condition>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Infanrix/Hib Single Injection Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix + Hiberix Separate Injection Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix™</intervention_name>
    <description>Intramuscular injection, one dose</description>
    <arm_group_label>Infanrix/Hib Single Injection Group</arm_group_label>
    <arm_group_label>Infanrix + Hiberix Separate Injection Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hiberix™</intervention_name>
    <description>Intramuscular injection, one dose</description>
    <arm_group_label>Infanrix/Hib Single Injection Group</arm_group_label>
    <arm_group_label>Infanrix + Hiberix Separate Injection Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol should be enrolled in the study.

          -  Subjects should have completed the full three-dose primary vaccination course in
             study 104567.

          -  A male or female child between, and including, 18 and 24 months of age at the time of
             the booster vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding booster vaccination, or planned use during
             the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the booster dose.

          -  Administration of a vaccine not foreseen by the study protocol within 30 days prior
             to vaccination, or planned administration during the study period, with the exception
             of measles or combined measles, mumps and rubella (MMR) vaccination.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Previous booster vaccination against diphtheria, tetanus, pertussis and/or
             Haemophilus influenzae type b diseases since the end of the primary study.

          -  History of diphtheria, tetanus, pertussis and/or Haemophilus influenzae type b
             diseases.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s).

          -  Major congenital defects or serious chronic illness.

          -  History of any progressive neurological disorders or seizures.

          -  Acute disease and/or fever at time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the booster dose or planned administration during the study period.

          -  Occurrence of any of the following adverse events (AEs) after previous administration
             of a diphtheria-tetanus-pertussis (DTP) vaccine:

               -  Hypersensitivity reaction due to any component of the vaccine.

               -  Encephalopathy.

               -  Fever ≥ 40.0 °C (axillary temperature) within 48 hours of vaccination.

               -  Collapse or shock-like state within 48 hours of vaccination.

               -  Persistent, inconsolable crying occurring within 48 hours of vaccination and
                  lasting ≥ 3 hours.

               -  Seizures with or without fever occurring within 3 days of vaccination.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liucheng County</city>
        <state>Guangxi</state>
        <zip>545200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mengshan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 21, 2012</lastchanged_date>
  <firstreceived_date>June 5, 2008</firstreceived_date>
  <firstreceived_results_date>July 17, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infanrix/Hib</keyword>
  <keyword>Chinese children</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infanrix/Hib Single Injection Group</title>
          <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
        </group>
        <group group_id="P2">
          <title>Infanrix + Hiberix Separate Injection Group</title>
          <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infanrix/Hib Single Injection Group</title>
          <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
        </group>
        <group group_id="B2">
          <title>Infanrix + Hiberix Separate Injection Group</title>
          <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="244"/>
                <measurement group_id="B2" value="223"/>
                <measurement group_id="B3" value="467"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19.2" spread="0.79"/>
                <measurement group_id="B2" value="19.2" spread="0.75"/>
                <measurement group_id="B3" value="19.2" spread="0.77"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="113"/>
                <measurement group_id="B2" value="111"/>
                <measurement group_id="B3" value="224"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="131"/>
                <measurement group_id="B2" value="112"/>
                <measurement group_id="B3" value="243"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in microgram per milliliter (μg/mL).</description>
        <time_frame>One month after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According To Protocol (ATP) cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="238"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations</title>
            <description>Geometric mean concentrations are given in microgram per milliliter (μg/mL).</description>
            <units>μg/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34.428" lower_limit="29.452" upper_limit="40.244"/>
                  <measurement group_id="O2" value="132.075" lower_limit="112.563" upper_limit="154.970"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-diphtheria Toxoid Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in international Unit per milliliter (IU/mL).</description>
        <time_frame>One month after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="214"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-diphtheria Toxoid Antibody Concentrations</title>
            <description>Geometric mean concentrations are given in international Unit per milliliter (IU/mL).</description>
            <units>IU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.945" lower_limit="0.905" upper_limit="0.987"/>
                  <measurement group_id="O2" value="0.926" lower_limit="0.887" upper_limit="0.966"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-tetanus Toxoid Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in IU/mL.</description>
        <time_frame>One month after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="214"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-tetanus Toxoid Antibody Concentrations</title>
            <description>Geometric mean concentrations are given in IU/mL.</description>
            <units>IU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.455" lower_limit="6.881" upper_limit="8.077"/>
                  <measurement group_id="O2" value="10.104" lower_limit="9.080" upper_limit="11.242"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
        <time_frame>One month after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="239"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations</title>
            <description>Geometric mean concentrations are given in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-PT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52.2" lower_limit="48.1" upper_limit="56.7"/>
                  <measurement group_id="O2" value="55.8" lower_limit="51.7" upper_limit="60.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-FHA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93.3" lower_limit="82.6" upper_limit="105.4"/>
                  <measurement group_id="O2" value="92.8" lower_limit="83.3" upper_limit="103.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRN</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="235.9" lower_limit="208.7" upper_limit="266.5"/>
                  <measurement group_id="O2" value="241.6" lower_limit="213.6" upper_limit="273.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</title>
        <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
        <time_frame>One month after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="239"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</title>
            <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Seroprotection against PRP (n=238, 216)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="238"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroprotection against diphtheria (n=237, 214)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="214"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroprotection against tetanus (n=237, 214)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="214"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seropositivity for anti-PT (n=239, 216)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="226"/>
                  <measurement group_id="O2" value="213"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seropositivity for anti-FHA (n=239, 216)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="238"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seropositivity for anti-PRN (n=239, 216)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="239"/>
                  <measurement group_id="O2" value="215"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PRP Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in μg/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-PRP Antibody Concentrations</title>
            <description>Geometric mean concentrations are given in μg/mL.</description>
            <units>μg/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.240" lower_limit="1.085" upper_limit="1.418"/>
                  <measurement group_id="O2" value="2.461" lower_limit="2.136" upper_limit="2.837"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-diphtheria Toxoid Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in IU/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="214"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-diphtheria Toxoid Antibody Concentrations</title>
            <description>Geometric mean concentrations are given in IU/mL.</description>
            <units>IU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.055" lower_limit="0.053" upper_limit="0.058"/>
                  <measurement group_id="O2" value="0.054" lower_limit="0.052" upper_limit="0.057"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-tetanus Toxoid Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in IU/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="214"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-tetanus Toxoid Antibody Concentrations</title>
            <description>Geometric mean concentrations are given in IU/mL.</description>
            <units>IU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.219" lower_limit="0.195" upper_limit="0.247"/>
                  <measurement group_id="O2" value="0.311" lower_limit="0.274" upper_limit="0.353"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</title>
        <description>Geometric mean concentrations are given in EL.U/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="239"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations</title>
            <description>Geometric mean concentrations are given in EL.U/mL.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-PT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  <measurement group_id="O2" value="10.0" lower_limit="10.0" upper_limit="10.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-FHA</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.1" lower_limit="10.0" upper_limit="10.2"/>
                  <measurement group_id="O2" value="10.3" lower_limit="9.9" upper_limit="10.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-PRN</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.2" lower_limit="10.0" upper_limit="10.4"/>
                  <measurement group_id="O2" value="10.3" lower_limit="10.0" upper_limit="10.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</title>
        <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
        <time_frame>Before booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the ATP cohort for immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="239"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies</title>
            <description>Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Seroprotection against PRP (n= 237, 216)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="236"/>
                  <measurement group_id="O2" value="216"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroprotection against diphtheria (n= 237, 214)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroprotection against tetanus (n= 237, 214)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="209"/>
                  <measurement group_id="O2" value="198"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seropositivity for anti-PT (n= 239, 216)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seropositivity for anti-FHA (n= 239, 216)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seropositivity for anti-PRN (n= 239, 216)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
        <time_frame>During the 4-day follow-up period after booster vaccination</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Analysis was performed on subjects from the Total Vaccinated Cohort with a documented dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="244"/>
                  <measurement group_id="O2" value="220"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Drowsiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 31-day follow-up period after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="244"/>
                  <measurement group_id="O2" value="223"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events (AE)</title>
            <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in isability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>During the 31-day follow-up period after booster vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Infanrix/Hib Single Injection Group</title>
            <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
          </group>
          <group group_id="O2">
            <title>Infanrix + Hiberix Separate Injection Group</title>
            <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="244"/>
                  <measurement group_id="O2" value="223"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Serious Adverse Events (SAE)</title>
            <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in isability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Infanrix/Hib Single Injection Group</title>
          <description>Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.</description>
        </group>
        <group group_id="E2">
          <title>Infanrix + Hiberix Separate Injection Group</title>
          <description>Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73"/>
                <counts group_id="E2" subjects_affected="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain at injection site</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Redness at injection site</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
